Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Multiple Sclerosis

Free Subscription 19.10.2026 1 BMC Neurol 1 Brain 1 J Immunol 1 J Neuroimmunol 1 J Neurol 2 J Neurol Sci 6 Mult Scler 1 Nat Rev Neurol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. UCAROGLU CAN N, Kotan D
   Elevated atherogenic index of plasma in multiple sclerosis: association with metabolic profile in a cross-sectional study.
   BMC Neurol. 2026;26:640.
   PubMed         Abstract available
   
   

   
   Brain

2. FREEMAN SA, Liblau RS
   A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis.
   Brain. 2026 Oct 17:awag360. doi: 10.1093.
   PubMed        
   
   

   
   J Immunol

3. TURNER TJ, Peterson SR, Alt LE, Aguilar Meza LS, et al
   TNFalpha promotes brain-predominant EAE independent of IFNgamma and IL-17A in HLA-DR3 transgenic mice.
   J Immunol. 2026;215:vkag268.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

4. GRUND E, Cross AH, Chahin S
   Multiple sclerosis: Advances in diagnosis, biomarkers, and disease management.
   J Neuroimmunol. 2026;422:579106.
   PubMed         Abstract available
   
   

   
   J Neurol

5. D'ORSO S, Picozza M, Guerrera G, Verdiani A, et al
   Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study.
   J Neurol. 2026;273:664.
   PubMed         Abstract available
   
   

   
   J Neurol Sci

6. MERLI N, Ferri C, Copetti M, Inchingolo V, et al
   Transorbital sonography reveals retrobulbar optic nerve neuroaxonal changes in multiple sclerosis.
   J Neurol Sci. 2026;491:126198.
   PubMed         Abstract available
   
   
7. GAGGIOLA M, Mauceri VA, Zanotelli G, Zoccarato M, et al
   Long-term outcomes of alemtuzumab in relapsing-remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab.
   J Neurol Sci. 2026;491:126210.
   PubMed         Abstract available
   
   

   
   Mult Scler

8. IAFFALDANO P, D'Amico S, Lucisano G, Copetti M, et al
   Validation of generative artificial intelligence techniques for synthetic data generation in multiple sclerosis research: A comparison with real-world evidence from the Italian multiple sclerosis registry.
   Mult Scler. 2026 Oct 14:13524585261492525. doi: 10.1177/13524585261492525.
   PubMed         Abstract available
   
   
9. WESSELS MHJ, de Jong DJ, Barrantes-Cepas M, Jelgerhuis JR, et al
   Survivor bias and disease progression in observational cohorts in multiple sclerosis.
   Mult Scler. 2026 Oct 14:13524585261490350. doi: 10.1177/13524585261490350.
   PubMed         Abstract available
   
   
10. ZBRZESKI C, Schorr EM, Polineni SP, Brandstadter R, et al
    How well do junior neurology residents recognize multiple sclerosis? Analysis of the "Close the Loop" resident clinical acumen project.
    Mult Scler. 2026 Oct 12:13524585261492141. doi: 10.1177/13524585261492141.
    PubMed         Abstract available
    
    
11. BUIJZE MSJ, Molenaar S, Verkerk R, Quist MA, et al
    Frequent early cognitive impairment in both pediatric MS and MOGAD.
    Mult Scler. 2026;32:1168-1181.
    PubMed         Abstract available
    
    
12. MALLADI AR, Abbasi Kasbi N, Cohen JA, Stuve O, et al
    Induced pluripotent stem cell treatment for microglia replacement in progressive MS.
    Mult Scler. 2026;32:1129-1138.
    PubMed         Abstract available
    
    
13. TACCHINI M, Gamberini G, Dini M, Rossi C, et al
    Event-related potentials and behavioural correlates of cognitive functions in MS: An EEG study during symbol digit modalities test.
    Mult Scler. 2026;32:1182-1192.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

14. KIANI L
    EBV reactivation precedes multiple sclerosis relapse.
    Nat Rev Neurol. 2026 Oct 9. doi: 10.1038/s41582-026-01280.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum